Sanjay Nayak Sells 1,759 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Sanjay Nayak sold 1,759 shares of Ocular Therapeutix stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $8.28, for a total transaction of $14,564.52. Following the completion of the transaction, the insider directly owned 330,653 shares of the company’s stock, valued at $2,737,806.84. The trade was a 0.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Sanjay Nayak also recently made the following trade(s):

• On Thursday, February 12th, Sanjay Nayak sold 10,348 shares of Ocular Therapeutix stock. The shares were sold at an average price of $9.04, for a total value of $93,545.92.

Ocular Therapeutix Price Performance

NASDAQ OCUL traded up $0.55 on Wednesday, hitting $9.50. The company had a trading volume of 7,845,017 shares, compared to its average volume of 7,060,435. The company has a debt-to-equity ratio of 0.11, a current ratio of 15.39 and a quick ratio of 15.32. The company’s fifty day moving average price is $10.53 and its 200-day moving average price is $11.62. The company has a market capitalization of $2.07 billion, a PE ratio of -6.60 and a beta of 0.90. Ocular Therapeutix, Inc. has a 12-month low of $5.78 and a 12-month high of $16.44.

Ocular Therapeutix (NASDAQ:OCUL) last announced its earnings results on Thursday, February 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. Ocular Therapeutix had a negative return on equity of 70.68% and a negative net margin of 511.90%.The business had revenue of $13.25 million during the quarter, compared to analysts’ expectations of $16.13 million. During the same quarter in the prior year, the firm earned ($0.29) earnings per share. The business’s revenue was down 22.4% compared to the same quarter last year. As a group, analysts predict that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current year.

Analysts Set New Price Targets

OCUL has been the subject of several analyst reports. Citigroup reiterated an “outperform” rating on shares of Ocular Therapeutix in a research report on Tuesday, February 17th. Jefferies Financial Group reiterated a “buy” rating on shares of Ocular Therapeutix in a report on Tuesday, February 17th. Needham & Company LLC decreased their target price on shares of Ocular Therapeutix from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Friday, February 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ocular Therapeutix in a research note on Thursday, January 22nd. Finally, Wall Street Zen upgraded shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a report on Saturday, February 7th. Twelve research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.78.

Key Ocular Therapeutix News

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: Director Richard L. Lindstrom bought 60,229 shares at an average $7.66 (a ~32% increase in his stake) — a sizable insider purchase that signals confidence and provides direct demand support for the shares. Read More.
• Positive Sentiment: Ocular will present detailed SOL‑1 data at the 49th Macula Society meeting and host an investor webcast — a potential catalyst if data or management commentary clarifies commercial or clinical outlooks. Read More.
• Neutral Sentiment: The company will participate in March investor conferences, increasing visibility with institutional investors but not introducing new clinical data by itself. Read More.
• Neutral Sentiment: Several small institutional moves were reported (new / larger stakes by boutique managers). These are modest in dollar terms and mainly signal ongoing institutional interest rather than a major position shift. (No single large fund reported a material cut.)
• Negative Sentiment: Short interest jumped ~27.8% in February to ~14.7M shares (about 6.9% of shares outstanding) with a ~3.0 days‑to‑cover — higher shorting can amplify downside on negative news and adds volatility risk.
• Negative Sentiment: Multiple insiders sold shares in late Feb (including Pravin Dugel, Sanjay Nayak, Jeffrey Heier, Peter Kaiser and Nadia Waheed). While some sales are modest relative to holdings, the cluster of transactions can be perceived as a negative signal. Representative SEC disclosure: Read More.
• Negative Sentiment: Needham lowered its price target to $18 (from $20) — a downward adjustment from a sell‑side firm that could temper sentiment among growth/biotech investors. Read More.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Pale Fire Capital SE lifted its position in Ocular Therapeutix by 20.7% in the second quarter. Pale Fire Capital SE now owns 530,135 shares of the biopharmaceutical company’s stock valued at $4,920,000 after acquiring an additional 90,748 shares during the last quarter. Saturn V Capital Management LP grew its holdings in shares of Ocular Therapeutix by 21.8% during the second quarter. Saturn V Capital Management LP now owns 728,576 shares of the biopharmaceutical company’s stock worth $6,761,000 after purchasing an additional 130,385 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in shares of Ocular Therapeutix during the second quarter worth about $342,000. Allianz Asset Management GmbH lifted its holdings in shares of Ocular Therapeutix by 63.2% in the 2nd quarter. Allianz Asset Management GmbH now owns 61,200 shares of the biopharmaceutical company’s stock valued at $568,000 after purchasing an additional 23,700 shares during the last quarter. Finally, Panagora Asset Management Inc. lifted its holdings in shares of Ocular Therapeutix by 33.6% in the 2nd quarter. Panagora Asset Management Inc. now owns 296,546 shares of the biopharmaceutical company’s stock valued at $2,752,000 after purchasing an additional 74,542 shares during the last quarter. Institutional investors and hedge funds own 59.21% of the company’s stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.